Skip to content
Peptide research

Adipotide

Also known as Prohibitin-TP01 · FTPP
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic peptide designed to destroy blood vessels feeding white fat, binding prohibitin to trigger endothelial cell death, marketed for rapid fat loss. The case rests entirely on animal studies; there is no human trial evidence. The headline concern is dose-dependent kidney toxicity, documented in primates, with no long-term human safety data. Not an approved drug; human use relies on unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Adipotide (also known as FTPP or Prohibitin-TP01) is an experimental compound that takes a unique approach to fat loss: rather than suppressing appetite or boosting metabolism, it selectively targets and destroys the blood vessels that supply fat tissue, causing fat cells to die from lack of blood flow. Developed at MD Anderson Cancer Center, it contains a "homing" sequence that finds fat tissue blood vessels and a "kill" sequence that destroys them from the inside. The human trial was terminated; its publicly recorded reason does not establish a toxicity-related cause.

How it works in the body

Carries a cell-death signal (a sequence called KLAKLAK) directly to blood vessels feeding fat tissue. It binds to prohibitin on fat tissue blood vessels, gets absorbed into those endothelial cells, then destroys their mitochondria — causing the blood vessels (and the fat they feed) to die.

Research overview

Adipotide works by binding to a protein called prohibitin on the surface of blood vessel cells within fat tissue. Once attached, it is pulled inside the cell where its second component disrupts the cell's mitochondria, triggering cell death and cutting off blood supply to surrounding fat. In mouse studies, daily injections completely reversed diet-induced obesity within 27 days. A landmark 2011 primate study published in Science Translational Medicine showed obese monkeys lost 7-20% of body weight, with total body fat decreasing by nearly 39% and significant improvements in insulin resistance. Notably, lean animals showed no weight loss at the same doses. A Phase 1 human trial began in 2012 in obese prostate cancer patients, but the trial was later terminated; a toxicity-related reason has not been publicly established. No human results were ever published.

Who researches Adipotide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(13)

Rated by level of concern

  • Dose-dependent renal tubular toxicity observed in primates

    High

    PMID 22072637 (full text PMC3666164); ClinicalTrials.gov NCT01262664

  • Elevated serum creatinine indicating kidney stress (reversible upon cessation in animal studies)

    Moderate

    PMID 22072637 (full text PMC3666164)

  • Mild to marked glucosuria (glucose in urine)

    Moderate

    PMID 22072637 (full text PMC3666164)

  • Mild to moderate proteinuria (protein in urine)

    Moderate

    PMID 22072637 (full text PMC3666164)

  • Decreased serum phosphorus and potassium levels

    Moderate

    PMID 22072637 (full text PMC3666164)

  • Increased urinary renal epithelial cells indicating tubular damage

    Moderate

    PMID 22072637 (full text PMC3666164)

  • Histological findings of minimal-to-mild tubular degeneration and single-cell necrosis in kidneys

    Moderate

    PMID 22072637 (full text PMC3666164)

  • Mild dehydration at higher doses

    Moderate

    PMID 22072637 (full text PMC3666164)

  • Injection site reactions

    Low

    Mechanism-based; no primary-source quantification located in PMID 22072637, PMID 15133506, PMID 20103704, or NCT01262664

  • Fatigue reported in some preclinical observations

    Theoretical

    No primary source located; NCT01262664 has no posted results

  • No long-term human safety data available — all safety data from animal studies only

    High

    ClinicalTrials.gov NCT01262664 (API v2 record: status Terminated, 'Terminated per PI's request', actual enrollment 4, no results posted)

  • Potential off-target vascular effects in non-adipose tissues not fully characterized

    Moderate

    PMID 15133506 (Nat Med 2004); PMID 22072637 (full text PMC3666164)

  • Not approved for human use — any human use is entirely experimental and unregulated

    High

    ClinicalTrials.gov NCT01262664; no FDA or EMA approval on record

Interaction summary(8)

Rated by direction with this peptide

  • Nephrotoxic drugs (aminoglycosides, amphotericin B, cisplatin, high-dose vancomycin, calcineurin inhibitors)

    CautionHigh

    Adipotide's dose-limiting toxicity is proximal tubular injury, so co-exposure to agents that damage the same nephron segment risks additive and potentially non-reversible kidney damage. No human interaction data exist; this is mechanism-based extrapolation from the primate renal findings.

    Mechanism-based, grounded in the dose-dependent primate renal toxicity in PMID 22072637 (full text PMC3666164)

  • NSAIDs (ibuprofen, naproxen, ketorolac)

    CautionModerate

    NSAIDs blunt prostaglandin-mediated renal perfusion, which compounds adipotide-associated tubular injury and the dehydration observed at higher doses. Mechanism-based, no human data.

    Mechanism-based; established NSAID renal pharmacology plus the tubular injury and dehydration in PMID 22072637

  • Loop and thiazide diuretics

    CautionModerate

    Adipotide produced dehydration at higher doses and mild-to-moderate falls in serum potassium and phosphorus in primates; diuretics would amplify both the electrolyte wasting and the prerenal insult. Mechanism-based, no human data.

    PMID 22072637 (full text PMC3666164: dehydration, decreased serum potassium and phosphorus)

  • ACE inhibitors and ARBs

    CautionModerate

    Loss of efferent arteriolar tone during adipotide-associated volume depletion can precipitate an acute drop in GFR on top of existing tubular injury. Entirely mechanism-based - no interaction has been studied.

    Mechanism-based; standard RAAS-blockade renal hemodynamics plus volume depletion in PMID 22072637

  • Iodinated contrast media

    CautionModerate

    Contrast-associated nephropathy affects the same proximal tubule that adipotide injures, so contrast imaging during or shortly after exposure adds a second insult to the same tubule. Mechanism-based, no human data.

    Mechanism-based; contrast nephropathy pathophysiology plus the renal findings in PMID 22072637

  • Insulin and insulin secretagogues (sulfonylureas, meglitinides)

    CautionModerate

    Adipotide reduced insulin AUC by 36.2% (P=0.019) in obese monkeys and improved glucose tolerance in rodents independently of weight and food intake, so unchanged secretagogue or insulin doses could drive hypoglycemia. Animal data only; no human dosing experience.

    PMID 22072637 (full text PMC3666164); PMC3425411 (Diabetes 2012;61:2299-2310, weight- and food-intake-independent glucose tolerance)

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    CautionModerate

    Both produce glucosuria and osmotic volume loss, so the combination worsens dehydration and makes adipotide's glucosuria useless as an early warning sign of tubular injury. Mechanism-based.

    Mechanism-based; dose-dependent mild-to-marked glucosuria reported in PMID 22072637

  • Renally cleared drugs with a narrow safety margin (lithium, digoxin, metformin)

    CautionModerate

    Falling renal function during treatment can raise levels of drugs dependent on renal clearance; metformin is not narrow-therapeutic-index in the classic sense but carries an added lactic-acidosis concern in acute kidney injury. Mechanism-based extrapolation from the primate renal impairment.

    Mechanism-based; dose-dependent renal impairment documented in PMID 22072637

Known risks(13)

  • Dose-dependent renal tubular toxicity observed in primates

  • Elevated serum creatinine indicating kidney stress (reversible upon cessation in animal studies)

  • Mild to marked glucosuria (glucose in urine)

  • Mild to moderate proteinuria (protein in urine)

  • Decreased serum phosphorus and potassium levels

  • Increased urinary renal epithelial cells indicating tubular damage

  • Histological findings of minimal-to-mild tubular degeneration and single-cell necrosis in kidneys

  • Mild dehydration at higher doses

  • Injection site reactions

  • Fatigue reported in some preclinical observations

  • No long-term human safety data available — all safety data from animal studies only

  • Potential off-target vascular effects in non-adipose tissues not fully characterized

  • Not approved for human use — any human use is entirely experimental and unregulated

Drug interactions(4)

  • Nephrotoxic drugs (NSAIDs, aminoglycosides, cisplatin, etc.)

    High (theoretical)

    Given adipotide's dose-dependent renal tubular toxicity, concomitant use with other nephrotoxic agents would be expected to increase risk of kidney damage. This was a theoretical concern noted in preclinical assessment.

  • Anticoagulants / Antiplatelets

    Moderate (theoretical)

    Adipotide causes vascular disruption and endothelial cell apoptosis. Concurrent anticoagulant use could theoretically increase bleeding risk at sites of vascular damage.

  • Antihypertensives / Diuretics

    Moderate (theoretical)

    Adipotide was associated with dehydration and electrolyte changes (decreased phosphorus and potassium). Diuretics or antihypertensives could exacerbate these effects.

  • Other weight loss medications

    No formal interaction studies conducted. Combining with GLP-1 agonists or other anti-obesity agents could potentially cause excessive weight loss or compounding metabolic stress.

Research & benefits

Evidence base

Total Studies
12
Human Studies
1

Strong preclinical evidence in mice and nonhuman primates. A single Phase 1 human trial (NCT01262664) was initiated in 2012 at MD Anderson Cancer Center in obese patients with castrate-resistant prostate cancer. The trial evaluated five dose levels across a 28-day subcutaneous injection cycle. No human results have been published. The trial was terminated at the principal investigator's request; a toxicity-related reason was not established.

Researched for(8)

Rated by confidence in the evidence

  • Rapid weight loss in animal models (7.4-14.7% body weight reduction in 28 days in primates)

    Low

    Treated primates lost 7.4 to 14.7% body weight over 28 days; no human data exist.

    PMID 22072637 (Sci Transl Med 2011;3:108ra112, full text PMC3666164) only

  • Selective targeting of white adipose tissue vasculature without affecting lean body mass

    Low

    Mechanism confirmed in mice and primates; lean mass sparing is a secondary, less rigorous endpoint.

    PMID 15133506 (Nat Med 2004); PMID 22072637

  • Marked improvement in insulin resistance (insulin AUC decreased 36% in obese primates)

    Low

    In obese monkeys, adipotide lowered insulin AUC by 36% after four weeks of treatment.

    PMID 22072637 (Barnhart et al., Sci Transl Med 2011;3(108):108ra112, full text PMC3666164) — the primary source; it reports a 36.2% mean decrease in insulin AUC in obese rhesus monkeys after 28 days of adipotide. The dose-finding experiment reported insulin AUC decreases of 61.4% and 63.5% in two monkeys; these are separate from the 36.2% mean decrease in the fixed-dose experiment.

  • Reduction in total body fat by approximately 38.7% in treated primates vs 14.8% in controls

    Speculative

    Single primate study; controls also lost 14.8% fat, so the treatment effect is smaller than it appears.

    PMID 22072637 (full text PMC3666164)

  • Decreased abdominal circumference and BMI in obese primates

    Speculative

    Single small primate study: BMI fell 3.7 to 17.3% and waist size 6.5 to 14.3% in most treated animals.

    PMID 22072637 (full text PMC3666164)

  • No weight loss effect in lean animals, suggesting selectivity for excess adipose tissue

    Low

    Confirmed in rodents and lean primates; supports a fat-selective mechanism, but evidence is animal-only.

    PMID 20103704 (Diabetes 2010;59:907-915); PMID 22072637 (full text PMC3666164)

  • Preserved lean body mass during treatment in long-term mouse studies

    Speculative

    Fat and lean mass were directly measured by nuclear magnetic resonance; the longer experiment lasted 27 days, so it does not establish long-term preservation.

    PMID 20103704 (Kim, Woods & Seeley, Diabetes 2010) — fat and lean mass were directly measured by nuclear magnetic resonance in experiments lasting 4 or 27 days, so this does not establish long-term lean-mass preservation; the mechanistic basis for lean-mass sparing comes from adipotide's fat-selective vascular targeting rather than a quantified finding in this paper.

  • Distinct vascular-targeting mechanism versus GLP-1 agonists or metabolic modulators

    Low

    Targets fat-tissue vasculature via apoptosis, not receptors, but still reduces food intake in rodents.

    PMID 15133506 (Nat Med 2004, 10:625-32); PMID 20103704 (Diabetes 2010;59:907-915)

Benefits(8)

  • Rapid weight loss in animal models (7.4-14.7% body weight reduction in 28 days in primates)

  • Selective targeting of white adipose tissue vasculature without affecting lean body mass

  • Marked improvement in insulin resistance (insulin AUC decreased 36% in obese primates)

  • Reduction in total body fat by approximately 38.7% in treated primates vs 14.8% in controls

  • Decreased abdominal circumference and BMI in obese primates

  • No weight loss effect in lean animals, suggesting selectivity for excess adipose tissue

  • Preserved lean body mass during treatment in long-term mouse studies

  • Distinct vascular-targeting mechanism versus GLP-1 agonists or metabolic modulators

Key studies(4)

  1. Barnhart KF, Christianson DR, Hanley PW, et al.

    Science Translational Medicine

    2011

    Obese rhesus monkeys treated with adipotide at 0.43 mg/kg SC daily for 28 days lost 7.4-14.7% body weight. Total body fat decreased 38.7%. Insulin AUC decreased 36.2-63.5%. MRI and DEXA confirmed white adipose tissue reduction. Reversible renal tubular injury was the primary adverse effect.

  2. Kim DH, Woods SC, Seeley RJ

    Diabetes

    2010

    Daily SC injections at 3 mg/kg in mice completely reversed high-fat-diet-induced obesity within 27 days. 76% of mass reduction was from reduced caloric intake. Fat loss was the primary component while lean mass was preserved. No conditioned taste aversion or central nervous system toxicity observed.

  3. MD Anderson Cancer Center / Arrowhead Research Corporation

    ClinicalTrials.gov

    2012

    Phase 1 trial evaluating 28-day subcutaneous injection cycle across five dose levels in obese patients with castrate-resistant prostate cancer. Endpoints included maximum tolerated dose, pharmacokinetics, weight change, and disease progression. No results published; trial discontinued.

  4. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W

    Nature Medicine

    2004

    Original discovery paper demonstrating that the CKGGRAKDC-GG-D(KLAKLAK)2 peptide selectively homes to white adipose tissue vasculature via prohibitin binding and induces apoptosis in adipose endothelial cells, causing rapid weight loss in obese mice.

Regulation & availability

Why researchers look at it

The 2011 primate study in Science Translational Medicine showed obese monkeys lost 7-20% of body weight with a 39% reduction in total body fat — by selectively destroying blood vessels that feed fat tissue rather than suppressing appetite. The human trial was terminated, but a toxicity-related reason has not been established, and no human trial results were ever published. The vascular-targeting approach may yet inform future anti-obesity strategies.

Estimated cost
Phase 1 trial terminated; no results posted.
FDA status
Adipotide is not FDA-approved and is not eligible for compounding in the US. NCT01262664 was subsequently terminated at the principal investigator's request, with no results posted.
WADA status
Not specifically named on the WADA Prohibited List. However, as an unapproved experimental compound, it would likely fall under WADA S0 (Non-Approved Substances) category, which prohibits any pharmacological substance not addressed by other sections of the Prohibited List and with no current approval by any governmental regulatory health authority for human therapeutic use. Athletes should consider it prohibited.
Prescribability
No
Availability
Not approved for human use by any regulatory agency. Not prescribed or legally sold for human consumption. Clinical development discontinued ~2019.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(7)

  1. 2004
    Original discovery published in Nature Medicine by Kolonin, Pasqualini, and Arap at UT/MD Anderson, demonstrating prohibitin-targeting peptide causes rapid weight loss in obese mice
  2. 2010
    Kim, Woods, and Seeley publish expanded mouse study in Diabetes showing adipotide reverses diet-induced obesity and reduces food intake through novel adipose-vascular signaling
  3. 2011
    Landmark primate study published in Science Translational Medicine by Barnhart et al. demonstrating 11% average weight loss in obese rhesus monkeys over 28 days with improved insulin resistance
  4. 2012-01-04
    Arrowhead announces FDA acceptance of the IND permitting a Phase 1 adipotide trial at MD Anderson.
  5. 2012-07
    First patient dosed in Phase 1 clinical trial (NCT01262664) at MD Anderson Cancer Center in obese patients with castrate-resistant prostate cancer
  6. ~2019
    Phase 1 trial terminated. No human efficacy or safety results published. The recorded termination reason is the principal investigator's request; a toxicity-related explanation was not established.
  7. 2026
    Remains an experimental research compound only. Not approved by FDA or any regulatory authority. No active clinical trials.

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

What is Adipotide and how does it work?

Adipotide (FTPP) is an experimental peptidomimetic that targets blood vessels supplying white adipose tissue. Its homing sequence (CKGGRAKDC) binds prohibitin and ANXA2 receptors on fat tissue blood vessel endothelial cells, while the proapoptotic sequence D(KLAKLAK)2 disrupts their mitochondria, causing programmed cell death. This starves fat cells of blood supply, leading to fat tissue reduction.

Is Adipotide approved for human use?

No. Adipotide is not approved by the FDA or any regulatory authority for human use. A Phase 1 clinical trial was initiated in 2012 but the trial was subsequently terminated at the principal investigator's request. It remains an experimental research compound only.

What were the results in animal studies?

In obese rhesus monkeys, 28 days of treatment produced 7-15% body weight loss, 38.7% reduction in total body fat, and 36-64% improvement in insulin resistance. In mice, it completely reversed diet-induced obesity within 27 days. Lean animals showed no weight loss, suggesting selectivity for excess fat.

Why was Adipotide clinical development stopped?

The registry records termination at the principal investigator's request, without establishing a toxicity-related reason. Primate studies documented renal tubular toxicity. No results are posted in the registry.

How is Adipotide different from GLP-1 agonists like semaglutide?

Unlike GLP-1 receptor agonists that suppress appetite centrally, Adipotide works by directly destroying blood vessels feeding white adipose tissue, causing fat cell death through ischemic apoptosis. It represents a fundamentally different mechanism targeting the vasculature rather than appetite or metabolic pathways.